NTLA (Intellia Therapeutics, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by NTLA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | JOHN M LEONARD | President and CEO | Sell | — | — |
| 2026-07-24 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | — | — |
| 2026-07-06 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | — | — |
| 2026-07-06 | Michael P Dube | VP, Chief Accounting Officer | Sell | — | — |
| 2026-06-10 | Fred E Cohen | Director | A | — | — |
| 2026-06-10 | Muna Bhanji | Director | A | — | — |
| 2026-06-10 | Brian Goff | Director | A | — | — |
| 2026-06-10 | Frank Verwiel | Director | A | — | — |
| 2026-06-10 | WILLIAM J CHASE | Director | A | — | — |
| 2026-06-10 | JESSE GOODMAN | Director | A | — | — |
| 2026-06-10 | Georgia Keresty | Director | A | — | — |
| 2026-03-03 | JAMES BASTA | EVP, General Counsel | MIXED | — | — |
| 2026-03-03 | Eliana Clark | EVP, Chief Technical Officer | MIXED | — | — |
| 2026-03-03 | Birgit C Schultes | EVP, Chief Scientific Officer | A | — | — |
| 2026-03-03 | Edward J Dulac III | EVP, Chief Financial Officer | A | — | — |
| 2026-03-03 | David Lebwohl | EVP, Chief Medical Officer | A | — | — |
| 2026-03-03 | JOHN M LEONARD | President and CEO | A | — | — |
| 2026-03-03 | Michael P Dube | VP, Chief Accounting Officer | A | — | — |
| 2026-01-07 | Birgit C Schultes | EVP, Chief Scientific Officer | Sell | — | — |
| 2026-01-07 | Fred E Cohen | Director | Buy | — | — |
| 2026-01-07 | Michael P Dube | VP, Chief Accounting Officer | Sell | — | — |
| 2026-01-07 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | — | — |
| 2026-01-07 | Eliana Clark | EVP, Chief Technical Officer | Sell | — | — |
| 2026-01-07 | David Lebwohl | EVP, Chief Medical Officer | Sell | — | — |
| 2026-01-07 | JAMES BASTA | EVP, General Counsel | Sell | — | — |
| 2026-01-07 | JOHN M LEONARD | President and CEO | Sell | — | — |
| 2025-12-12 | JOHN M LEONARD | President and CEO | MIXED | — | — |
| 2025-10-03 | Michael P Dube | VP, Chief Accounting Officer | Sell | — | — |
| 2025-10-03 | Birgit C Schultes | EVP, Chief Scientific Officer | Sell | — | — |
| 2025-08-22 | WILLIAM J CHASE | Director | Buy | — | — |
| 2025-07-25 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | — | — |
| 2025-07-03 | Michael P Dube | VP, Chief Accounting Officer | Sell | — | — |
| 2025-07-03 | Eliana Clark | EVP, Chief Technical Officer | Sell | — | — |
| 2025-07-02 | JESSE GOODMAN | Director | Sell | — | — |
| 2025-06-18 | Georgia Keresty | Director | A | — | — |
| 2025-06-13 | JESSE GOODMAN | Director | A | — | — |
| 2025-06-13 | Muna Bhanji | Director | A | — | — |
| 2025-06-13 | WILLIAM J CHASE | Director | A | — | — |
| 2025-06-13 | Brian Goff | Director | A | — | — |
| 2025-06-13 | Frank Verwiel | Director | A | — | — |
| 2025-06-13 | Fred E Cohen | Director | A | — | — |
| 2025-05-01 | Muna Bhanji | Director | Sell | — | — |
| 2025-03-04 | Michael P Dube | VP, Chief Accounting Officer | A | — | — |
| 2025-03-04 | Birgit C Schultes | EVP, Chief Scientific Officer | A | — | — |
| 2025-03-04 | JOHN M LEONARD | President and CEO | A | — | — |
| 2025-03-04 | Edward J Dulac III | EVP, Chief Financial Officer | A | — | — |
| 2025-03-04 | Eliana Clark | EVP, Chief Technical Officer | MIXED | — | — |
| 2025-03-04 | David Lebwohl | EVP, Chief Medical Officer | A | — | — |
| 2025-03-04 | JAMES BASTA | EVP, General Counsel | MIXED | — | — |
| 2025-01-31 | Muna Bhanji | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,343,967 | — |
| — | 10%+ Owner | 4,129,903 | — |
| — | 10%+ Owner | 3,729,788 | — |
| — | 10%+ Owner | 3,659,788 | — |
| — | Director | 2,662,180 | — |
| — | Director | 2,603,646 | — |
| — | President and CEO | 1,208,264 | — |
| — | — | 796,683 | — |
| — | 10%+ Owner | 790,527 | — |
| — | President & CEO | 696,000 | — |
| — | EVP, General Counsel | 424,598 | — |
| — | Director | 349,612 | — |
| — | Director | 216,653 | — |
| — | EVP, General Counsel | 158,005 | — |
| — | EVP, Chief Financial Officer | 148,175 | — |
| — | Director | 143,893 | — |
| — | EVP, Chief Scientific Officer | 137,733 | — |
| — | EVP, Chief Medical Officer | 131,192 | — |
| — | EVP, Chief Technical Officer | 93,864 | — |
| — | EVP, Chief Scientific Officer | 77,388 | — |
| — | EVP, Chief Financial Officer | 69,213 | — |
| — | VP, Chief Accounting Officer | 66,886 | — |
| — | EVP, Chief Business Officer | 59,878 | — |
| — | Director | 45,416 | — |
| — | Director | 41,083 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NTLA quote page; the site-wide leaderboard is on the insider transactions hub.